Associations of genetic variants of endothelin with cardiovascular complications in patients with renal failure

BMC Nephrology

Table 3 Association analysis of genetic polymorphisms of the EDN1 gene and cardiovascular disease susceptibility in end-stage renal disease patients

		Cardiovascular disease susceptibility			Recessive
rs number	Genotype	Cases (%)	Control (%)	OR (95% CI)	p value	q-value
rs3087459	CC	3 (3%)	3 (5.8%)	0.06 (0.01–0.69)	0.019	0.086
	CA	26 (25.7%)	13 (25%)	1
	AA	72 (71.3%)	36 (69.2%)	1
rs2248580	CC	8 (7.8%)	12 (21.8%)	0.10 (0.02–0.47)	0.001	0.013
	CA	49 (48.0%)	22 (40.0%)	1
	AA	45 (44.1%)	21 (38.2%)	1
rs2070699	GG	11 (11.7%)	16 (29.6%)	0.09 (0.02–0.38)	<.001	0.003
	GT	50 (53.2%)	22 (40.7%)	1
	TT	33 (35.1%)	16 (29.6%)	1
rs5370	TT	5 (2.5%)	4 (10.0%)	0.30 (0.04–2.08)	0.216	0.388
	TG	32 (40.0%)	20 (32.2%)	1
	GG	61 (57.5%)	28 (57.8%)	1
rs4714384	TT	7 (7.2%)	14 (26.9%)	0.05 (0.01–0.23)	<.001	<.001
	TC	42 (43.3%)	17 (32.7%)	1
	CC	48 (49.5%)	21 (40.4%)	1

p values were adjusted for age, sex, smoking, diabetes, hypertension, pre-existing cardiovascular events, hemoglobin, albumin, ferritin, and the erythropoietin resistance index. p and q-values of <0.05 are shown in bold. q-values of <0.05 were considered statistically significant after correction for multiple testing. OR, odds ratio; CI, confidence interval

ISSN: 1471-2369